INTRODUCTION {#S1}
============

High-dose chemotherapy followed by autologous hematopoietic cell transplantation is widely used to treat persons with multiple myeloma (MM). However, there is no standard therapy for those who relapse \[[@R1], [@R2]\]. The outcome of those relapsing after autotransplantation and are also refractory to proteasome inhibitors and immunomodulatory agents is particularly poor \[[@R3]\]. Options for relapsed patients include clinical trials, second autotransplants or an allogeneic stem cell hematopoietic cell transplant. Because of the high morbidity and mortality associated with myeloablative allogeneic transplantation, lower intensity conditioning regimens such as non-myeloablative (NST) or reduced-intensity conditioning (RIC) allogeneic transplants \[[@R4]\] are more commonly used.

There are limited data on the outcomes of NST/RIC in persons with myeloma failing an autotransplant. We used the Center for International Blood and Marrow Transplant Research (CIBMTR) database to compare outcomes of a 2^nd^ autotransplant versus NST/RIC allotransplantation in this setting.

PATIENTS AND METHODS {#S2}
====================

Data source {#S3}
-----------

The CIBMTR is a voluntary working group of more than 450 transplantation centers worldwide that contribute detailed data on consecutive allogeneic and autologous transplants to a statistical center at the Medical College of Wisconsin. Participating centers are required to register all transplants consecutively; compliance is monitored by on-site audits. Patients are followed up longitudinally, with yearly follow-up. Computerized checks for errors, physicians' review of submitted data, and on-site audits of participating centers ensure data quality. Observational studies conducted by the CIBMTR are performed with a waiver of informed consent and in compliance with Health Insurance Portability and Accountability Act regulations as determined by the institutional review board and the privacy officer of the Medical College of Wisconsin. All CIBMTR centers contribute to the registration data. Research data are collected on subset of registered patients and include detailed disease and pre-transplantation and post-transplantation clinical information.

Patients {#S4}
--------

The study population comprised of MM patients \<65 years who had relapsed/progressed after prior autologous transplant and subsequently received NST/RIC allogeneic transplant or a 2^nd^ autotransplant between 1995 and 2008. The age limit of 65 was used since most transplant centers would not perform full myeloablative allogeneic transplants in patients 65 or older.

Recipients of planned tandem transplants (n = 931) were excluded from the study. The following allogeneic transplant recipients were excluded: those receiving NST/RIC for graft failure (n = 15) or second malignancies (n = 4) as well as patients who received cord blood transplants (n = 2).

Definitions {#S5}
-----------

The intensity of conditioning regimens was categorized as RIC or NST using established consensus criteria \[[@R5]\]. Previously established criteria for categorizing the degree of HLA matching were used for unrelated donor transplants \[[@R6]\].

Study Endpoints and statistical analysis {#S6}
----------------------------------------

Primary outcomes were non-relapse mortality (NRM), progression/relapse, progression-free survival (PFS), and overall survival (OS) after the second transplant. NRM was defined as death from any cause within the first 28 days after transplantation or death thereafter in the absence of relapse/progression. Relapse/progression was defined according to the standard EBMT/IBMTR/ABMTR criteria. Probabilities of NRM and myeloma progression/relapse were calculated using cumulative incidence curves to accommodate competing risks \[[@R8], [@R9]\]. OS interval was defined as the time from second transplant to death from any cause. PFS interval was defined as the time from second transplant to relapse/progression or death from any cause whichever occurs first. Patients alive without evidence of disease relapse/progression were censored at last follow up. Probabilities of PFS and OS were calculated using the Kaplan-Meier product limit estimate. Other outcomes analyzed included acute and chronic graft versus-host disease (GVHD) and cause of death. Acute GVHD was defined and graded based on the pattern and severity of organ involvement using established criteria \[[@R7]\]. Chronic GVHD was defined as the development of any chronic GVHD based on clinical criteria. Both of these events were summarized by the corresponding cumulative incidence estimate, with death without development of GVHD as the competing risk.

Associations between patient-, disease-, and transplant-related factors and survival were assessed using multivariate Cox proportional hazards regression \[[@R10]\]. The variables considered in the multivariate analysis were: age (\< 50 vs. ≥ 50), sex, Karnofsky performance score (KPS), Durie-Salmon (DS) stage, immunochemical subtype of MM, conditioning regimen for second transplant, interval from diagnosis to first transplant, interval from first transplant to relapse/progression, time interval from first to second transplant and the year of second transplant. Stepwise variable selection at a 0.05 significance level was used to identify covariates. In the model, the assumption of proportional hazards was tested for each variable using a time-dependent covariate and graphical methods. All variables considered in the multivariate analysis satisfied the proportionality assumption. All computations were made using the statistical package SAS version 9.1 (SAS Institute, Cary, NC).

RESULTS {#S7}
=======

Subject-, Disease-, and Transplant-Related Variables ([Table 1](#T1){ref-type="table"}) {#S8}
---------------------------------------------------------------------------------------

Between 1995 and 2008, 152 subjects received NST/RIC (32 from HLA-identical siblings and 120 from HLA-matched unrelated donors) for relapsed/progressive MM after a prior autotransplant. 137 subjects received a 2^nd^ autotransplant in the same setting. Median follow-up of NST/RIC survivors is 30 months (range, 2--98 months) and 29 months for patients who underwent a 2^nd^ autotransplant (range, 3--97 months). The NST/RIC cohort was younger: median age, 53 years versus 56 years (p = 0.001). Gender distribution and Karnofsky performance score (KPS) were similar.

There was a higher proportion of pts with IgG MM in the autotransplantation cohort (p = 0.004). Stage at diagnosis was similar with 58% of patients in Durie-Salmon stage III in both cohorts.

As expected, conditioning regimens differed between cohorts. Most (85%) recipients of 2^nd^ autotransplant received high-dose melphalan alone. Melphalan containing regimens were used in only 43% of the NST/RIC group. Only 4% of the autotransplant cohort received total body irradiation as part of their conditioning, in contrast to 29% of the NST/RIC.

The amount of missing myeloma related data---beta-2 microglobulin, albumin, and response status prior to 2^nd^ transplant---between the two groups was strikingly different, with 25% of the NST/RIC patients having these data available. There was no meaningful way to compare the disease state prior to transplant in the 2 cohorts. Among autotransplant recipients 54 (39%) were in complete or partial remission where as 78% of the NST/RIC cohort had missing disease status data.

Median interval from diagnosis to first transplant was similar in both cohorts. In contrast, interval from 1^st^ transplant to relapse/progression was significantly shorter in the NST/RIC cohort: 12 months (range, \< 1--61 months) vs. 17 months (range, \< 1--121 months; p = 0.009) in the autotransplant cohort. Interval from 1^st^ to 2^nd^ transplants was also shorter for the NST/RIC cohort, 23 months (range 6--78 months) versus 30 months (range, 6--122 months; p = 0.014). Between 1995 and 2000, comparable numbers of patients were salvaged with autotransplants and NST/RIC, but between 2001 and 2006, NST/RIC appeared to be favored, while from 2007--2008, the trend appeared to reverse itself, favoring autotransplantation. One-half of subjects receiving an autotransplant received maintenance therapy, but only 11% of the NST/RIC group was reported to receive maintenance; comparisons are again confounded by missing maintenance data for 58% of patients in the NST/RIC group.

Patient outcomes {#S9}
----------------

[Table 2](#T2){ref-type="table"} demonstrates unadjusted outcomes. Platelet engraftment at 28 and 60 days was inferior in the NST/RIC group. NRM ([Figure 1](#F1){ref-type="fig"}) was 13% (95% CI, 8--19) at one year for subjects receiving NST/RIC versus 2% (95% CI, 1--5%) for AHCT recipients (p = \< 0.001). Three-year probabilities of NRM were 14% (95% CI, 9--20) versus 4% (95% CI, 2--8; p ≤ 0.001). Relapse rates differed at 12 months, favoring the autotransplant group, but this difference did not persist long term ([Figure 2](#F2){ref-type="fig"}). There was a trend toward better 5-year progression rates in the NST/RIC group. PFS results also favored the autotransplant group, with the most striking differences at 12 and 36 months ([Figure 3](#F3){ref-type="fig"}). Finally, OS was far superior at all time points in the autotransplant group ([Figure 4](#F4){ref-type="fig"}).

The multivariate analyses were limited by the quality of data requested in the forms (insufficient cytogenetic and FISH data) and the quality of data provided for the patients in the NST/RIC group. Factors that affected overall mortality included NST/RIC (HR 2.38, 95%, CI, 1.79--3.16, p = \<0.001), year of 2^nd^ transplant (HR 0.57, 0.43--0.75, p = \<0.001) for patients transplanted in later time periods, and functional status (HR1.96, 1.47--2.62, p = \<0.001). In multivariate analyses ([Table 3](#T3){ref-type="table"}) allotransplants were associated with a higher risk of NRM (HR 7.14, 95% CI, 2.70--8.91; p = 0.001) and death (HR 2.38, 95% CI, 1.79 -- 3.16; p \< 0.001). Effect of therapy on treatment failure was only significant in subjects with Durie-Salmon stage III. In these patients, allotransplant is associated with a higher risk of relapse and treatment-failure compared to autotransplantation (HR 3.05, 95% CI, 2.20--4.22; p = 0.001).

Patients who underwent NST/RIC from related and unrelated donors had a similar outcome. The PFS and OS were similar at 1, 3 and 5 years (data not shown). The 3-year OS of patients who underwent NST/RIC from related donors was 19% (95% CI, 7--33) compared to patients whose donors were unrelated, 21% (95% CI, 14--28; p = 0.82). The TRM was also similar irrespective of donor type (HR 1.077, 95% CI 0.75--1.54, p = 0.68).

DISCUSSION {#S10}
==========

The optimal therapy for patients with resistant or relapsed MM after autotransplantation remains unknown. The immunomodulatory agents and proteosome inhibitors have greatly expanded the therapeutic armamentarium against MM and many patients can benefit from additional therapy after autotransplant relapse. However, the disease eventually progress or patients develop unacceptable toxicities that limit these therapies. Since autotransplantation induces durable remissions with acceptable toxicity, a second autotransplant is also a consideration. Several studies have documented that this approach is feasible and transplant centers frequently harvest enough stem cells for two transplants in preparation for a second autotransplant upon MM progression or relapse \[[@R11]--[@R17]\]. Other investigators prefer the use of allogeneic transplantation because the graft is free of tumor and has the potential to induce a graft-versus-MM effect \[[@R18]--[@R28]\]. Since the morbidity and mortality associated with myeloablative allogeneic transplantation is high, most centers have relied on low-intensity conditioning NST/RIC. The aim of our study was to have a better understanding whether one type of transplant was favored for patients with relapse/refractory MM requiring salvage transplantation.

Our data demonstrate that patients who undergo autotransplantation rather than NST/RIC as their second transplant fare better across all measures including rates of progression. Major limitations of this study are the absence of cytogenetic data and a paucity of other prognostic factors available in the NST/RIC cohort. The autotransplant cohort was lower risk based on a longer time interval from 1^st^ autotransplant to relapse.

If one compares these registry data to small series from individual institutions, our NRM is lower. The CIBMTR registry 1-year NRM for RIC/NST was 13% as compared to single institution reporting NRM varying from 11% to 26% \[[@R18]--[@R28]\]. An EBMTR analysis of large number of patients who underwent RIC/NST, most of them after autotransplant failure, reported a NRM of 22% \[[@R29]\]. Our results are remarkable when it is taken into consideration that 90% of the patients in this study underwent unrelated RIC/NST. Despite the lower NRM, both PFS and OS in the current study are lower than what has been reported in other studies: OS (24%--74%) and DFS (21%--61%) \[[@R18]--[@R28]\]. These differences may be in part a reflection of patient selection since most of these studies were from single institutions and had smaller numbers of patients.

The outcome of patients who underwent 2^nd^ autotransplants in this study is similar to previously published reports despite the fact that we only included patients younger than 66 years of age \[[@R11]--[@R17]\].

In a biologic assignment trial comparing patients who underwent tandem autotransplants to patients who underwent autotransplants followed by NSC as their initial therapy for myeloma, the 3-year DFS and OS was similar. However, the NRM was higher in the autologous-NSC arm of the study, as observed in our study.

Our study has several strengths and limitations. Strengths include the large number of patients from multiple centers who contributed cases to this study over a long period of time, reflecting more accurately the practice of transplantation throughout this period. Limitations include the lack of information regarding prognostic factors including cytogenetics and International Staging System stage, information on maintenance therapy and the disease status at the time of alloHCT. With these caveats in mind, the conclusion from these data is that patients who undergo autotransplants as their second transplant fare better than NST/RIC across all measures including progression rates and NRM. Since disease status was not available for most allotransplant recipients, is not possible to determine which type of transplant is superior after autotransplant failure.
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![Non-relapsed mortality (NRM) after second hematological cell transplant by type of second transplant\
This figure describes the cumulative incidence rate of NRM after second hematological cell transplant by type of second transplant, which are second salvage autologous transplant and allogeneic transplant](nihms531253f1){#F1}

![Relapse rate (REL) after second hematological cell transplant by type of second transplant\
This figure describes the cumulative incidence rate of TRM after second hematological cell transplant by type of second transplant, which are second salvage autologous transplant and allogeneic transplant](nihms531253f2){#F2}

![Progression-free survival (PFS) after second hematological cell transplant by type of second transplant\
This figure describes the probability estimates of PFS after second hematological cell transplant by type of second transplant, which are second salvage autologous transplant and allogeneic transplant](nihms531253f3){#F3}

![Overall survival (OS) after second hematological cell transplant by type of second transplant\
This figure describes the probability estimates of OS after second hematological cell transplant by type of second transplant, which are second salvage autologous transplant and allogeneic transplant](nihms531253f4){#F4}

###### 

Characteristics of patients who underwent second autologous, HLA-identical or unrelated non-myeloablative/reduced intensity conditioning transplantation as therapy for persistent or recurrent disease after autologous transplantation for Multiple Myeloma in North American, reported to CIBMTR between 1995 and 2008.

  Characteristics of patients                                    Autologous      Allogeneic     P-value
  -------------------------------------------------------------- --------------- -------------- -----------------------------------------
  **[Patients-related]{.ul}**                                                                   
  Number of patients                                             137             152            
  Number of centers                                              54              65             
  Age at 2nd transplant, median (range), years                   56 (28--65)     53(32--65)     0.001[\*](#TFN2){ref-type="table-fn"}
   18--29                                                        1 (\<1)         0 (0)          0.039[\*](#TFN2){ref-type="table-fn"}
   30--39                                                        4 ( 3)          9 ( 6)         
   40--49                                                        32 (23)         47 (31)        
   50--59                                                        60 (44)         72 (47)        
   60--65                                                        40 (29)         24 (16)        
  Gender                                                                                        
   Male                                                          84 (61)         90 (59)        0.720
  Karnofsky score pre-transplant                                                                
   ≥90%                                                          68 (50)         76 (50)        0.884
   \<90%                                                         55 (40)         63 (41)        
   Missing                                                       14 (10)         13 ( 9)        
  **[Disease-related]{.ul}**                                                                    
  Immunochemical subtype of MM                                                                  
   IgG                                                           67 (49)         63 (41)        0.004[\*](#TFN2){ref-type="table-fn"}
   IgA                                                           20 (15)         37 (24)        
   Light chain                                                   26 (19)         36 (24)        
   Others[a](#TFN3){ref-type="table-fn"}                         7 ( 5)          12 ( 8)        
   Missing                                                       17 (12)         4 ( 3)         
  Durie-Salmon stage at diagnosis                                                               
   Stage I                                                       8 ( 6)          13 ( 9)        0.293
   Stage II                                                      32 (23)         41 (27)        
   Stage III                                                     80 (58)         88 (58)        
   Missing                                                       17 (13)         10 ( 7)        
  Percent of plasma cell prior to transplant                     6 (1--95)       12 (1--95)     \-\--
   Evaluable                                                     85 (62)         27 (18)        
  Albumin prior to transplant                                                                   
   \<3.5 g/dL                                                    44 (32)         12 (8)         \-\--
   ≥3.5g/dL                                                      88 (64)         20 (13)        
   Missing                                                       5 ( 4)          120 (79)       
  β~2~-microglobulin level prior to transplant                                                  
   \<3.5 mg/L                                                    63 (46)         19 (13)        \-\--
   ≥3.5 mg/L                                                     22 (16)         6 ( 4)         
   Missing                                                       52 (38)         127 (84)       
  **[Transplant-related]{.ul}**                                                                 
  Conditioning regimen                                                                          
   Melphalan alone                                               116 (85)        3 ( 2)         \<0.001[\*](#TFN2){ref-type="table-fn"}
   Melphalan + TBI ± others                                      4 ( 3)          7 ( 5)         
   Melphalan (no TBI) + others                                   11 ( 8)         58 (38)        
   TBI (no Melphalan) ± others                                   2 ( 1)          37 (24)        
   Busulfan + cyclophosphamide ± others                          3 ( 2)          1 (\<1)        
   Busulfan + fludarabine ± others                               0 ( 0)          30 (20)        
   Cyclophosphamide + fludarabine ± others                       0 ( 0)          16 (11)        
   Others[b](#TFN4){ref-type="table-fn"}                         1 (\<1)         0 (0)          
  Disease status prior 2nd transplant                                                           
   CR/PR                                                         54 (39)         1(\<1)         \<0.001[\*](#TFN2){ref-type="table-fn"}
   MR/NR/SD                                                      60 (44)         7 (5)          
   Relapse/progression                                           23 (17)         25 (16)        
   Missing                                                       \--             119 (78)       
  Graft type                                                                                    
   Bone marrow                                                   0 ( 0)          26 (17)        \<0.001[\*](#TFN2){ref-type="table-fn"}
   Peripheral blood                                              137(100)        126 (83)       
  Donor type                                                                                    
   Related                                                       \--             32             
   Unrelated                                                     \--             120            
  Reason for 2nd transplant                                                                     
   Persistent malignancy                                         54 (39)         57 (38)        0.809
   Recurrent malignancy                                          83 (61)         95 (62)        
  Donor age, years                                               NA              37 (19--78)    \-\--
  Donor-recipient sex match                                                                     
   Male-Male                                                     NA              65 (43)        \-\--
   Male-Female                                                   NA              25 (16)        
   Female-Male                                                   NA              33 (22)        
   Female-Female                                                 NA              29 (19)        
  GVHD prophylaxis                                                                              
   FK506+MTX ± other                                             NA              53 (35)        \-\--
   FK506 ± other                                                 NA              41 (27)        
   MTX+CSA ± other                                               NA              9 ( 6)         
   CSA ± other                                                   NA              49 (32)        
  RIC vs. Non-myeloablative                                                                     
   RIC                                                           NA              111 (73)       \-\--
   Non-myeloablative                                             NA              41 (27)        
  Time from diagnosis to 1st transplant, median(range), months   7 (4--69)       8 (\<1--119)   0.114
   \<12 months                                                   102 (74)        110 (72)       0.790
   ≥12 months                                                    35 (26)         42 (28)        
  Time from 1st transplant to relapse/progression, months        17 (\<1--121)   12 (\<1--61)   0.009[\*](#TFN2){ref-type="table-fn"}
   \<6 months                                                    26 (19)         36 (24)        0.135
   6--12 months                                                  22 (16)         27 (18)        
   12--24 months                                                 39 (28)         31 (20)        
   24--36 months                                                 24 (18)         14 ( 9)        
   \>36 months                                                   26 (19)         17 (11)        
   Missing                                                       0 ( 0)          27 (18)        
  Time from 1st to 2nd transplant, median(range), months         30 (6--122)     23 (6--78)     0.014[\*](#TFN2){ref-type="table-fn"}
   12--24 months                                                 44 (32)         78 (51)        0.001[\*](#TFN2){ref-type="table-fn"}
   \>24 months                                                   93 (68)         74 (49)        
  Year of transplant                                                                            
   1995--1996                                                    3 ( 2)          0 ( 0)         \<0.001[\*](#TFN2){ref-type="table-fn"}
   1997--1998                                                    5 ( 4)          3 ( 2)         
   1999--2000                                                    9 ( 7)          11 ( 7)        
   2001--2002                                                    16 (12)         28 (18)        
   2003--2004                                                    26 (19)         47 (31)        
   2005--2006                                                    39 (28)         54 (36)        
   2007--2008                                                    39 (28)         9 ( 6)         
  **[Post-transplant]{.ul}**                                                                    
  Maintenance therapy                                                                           
   No                                                            68 (50)         47 (31)        \<0.001
   Yes                                                           69 (50)         17 (11)        
   Missing                                                       0               88 (58)        
  DLI given                                                                                     
   Yes                                                           0               19 (13)        \<0.001
   No                                                            137 (100)       133 (88)       
  Median follow-up of survivors (range), months                  29 (3--97)      30 (12--98)    

[Abbreviations]{.ul}: TBI = total body irradiation; RIC = reduced intensity; conditioning; FK506 = tacrolimus; CSA = cyclosporine; MTX = methotrexate.

Follow-up completeness index as of 12/31/2009: @ 1year (96%), @ 3 year (92%), and @ 5 year 91%.

Other immunochemical subtype includes: ***[Autologous]{.ul}***: non-secretory (n=5), IgD (n=1), and IgM (n=1)***[Allogeneic]{.ul}***: non-secretory (n=11), and IgD (n=1)

Others conditioning regimen ***[Autologous]{.ul}***: CY+ARAC+ETOP+NITRO (n=1)

###### 

Unadjusted univariate analysis

  Outcomes                            Autologous   NST/RIC       P-value                 
  ----------------------------------- ------------ ------------- --------- ------------- -----------------------------------------
  Engraftment                                                                            
   ANC ≥ 500/mm^3^                                                                       
    @ 28 days                         137          96 (92--98)   152       96 (93--98)   0.999
   Platelets ≥ 20 × 10^9^/L                                                              
    @ 28 days                         137          90 (84--94)   152       77 (70--83)   0.007[\*](#TFN5){ref-type="table-fn"}
    @ 60 days                         137          93 (89--97)   152       84 (78--89)   0.009[\*](#TFN5){ref-type="table-fn"}
  Acute graft-versus-host disease                                                        
    @ 30 days                                      NA            152       21 (15--28)   \--
    @ 60 days                                      NA                      35 (28--43)   \--
  Chronic graft-versus-host disease                                                      
    @ 12 months                                    NA            152       42 (34--50)   \--
    @ 36 months                                    NA                      44 (36--52)   \--
  Relapse/Progression                                                                    
    @ 12 months                       137          53 (44--61)   152       72 (64--79)   \<0.001[\*](#TFN5){ref-type="table-fn"}
    @ 36 months                       137          84 (76--90)             80 (73--86)   0.655
    @ 60 months                       137          91 (85--96)             83 (77--89)   0.046[\*](#TFN5){ref-type="table-fn"}
  Non-relapse mortality                                                                  
    @ 12 months                       137          2 (1--5)      152       13 ( 8--19)   \<0.001[\*](#TFN5){ref-type="table-fn"}
    @ 36 months                                    4 (2--8)                14 ( 9--20)   \<0.001[\*](#TFN5){ref-type="table-fn"}
    @ 60 months                                    4 (2--8)                15 (10--21)   \<0.001[\*](#TFN5){ref-type="table-fn"}
  Progression free survival                                                              
    @ 12 months                       137          45 (37--54)   152       15 (10--21)   \<0.001[\*](#TFN5){ref-type="table-fn"}
    @ 36 months                                    12 (7--19)              6 ( 3--10)    0.038[\*](#TFN5){ref-type="table-fn"}
    @ 60 months                                    4 (1--11)               2 (\<1--5)    0.235
  Overall survival                                                                       
    @ 100 days                        137          97 (91--98)   152       77 (69--83)   \<0.001[\*](#TFN5){ref-type="table-fn"}
    @ 12 months                                    82 (75--88)             51 (42--58)   \<0.001[\*](#TFN5){ref-type="table-fn"}
    @ 36 months                                    46 (37--55)             20 (14--27)   \<0.001[\*](#TFN5){ref-type="table-fn"}
    @ 60 months                                    29 (20--40)             9 ( 5--15)    \<0.001[\*](#TFN5){ref-type="table-fn"}

significant difference

NST/RIC = non-myeloablative stem cell transplant/reduced intensity conditioning

###### 

Multivariate Analysis

  Factor                                                            Level                  N      HR               95% CI    P-value
  ----------------------------------------------------------------- ---------------------- ------ ---------------- --------- ---------------------------------------
  OS                                                                                                                         
  Main effect                                                       Auto                   137    1                          
  NST/RIC                                                           152                    2.38   (1.79 -- 3.16)   \<0.001   
  Year of 2^nd^ transplant                                          1995--2004             148    1                          
  2005--2008                                                        141                    0.57   (0.43 -- 0.75)   \<0.001   
  Karnofsky score                                                   ≥ 90                   144    1                          0.001[\*](#TFN7){ref-type="table-fn"}
  \<90                                                              118                    1.96   (1.47 -- 2.62)   \<0.001   
  Missing                                                           27                     1.85   (1.14 -- 3.01)   0.013     
  Treatment failure                                                                                                          
  Interactional effect between main effect and Durie-Salmon Stage   DS stage I--II, Auto   40     1                          
  DS stage I--II, NST/RIC                                           54                     1.33   (0.87--2.02)     0.189     
  DS stage III, Auto                                                80                     1                                 
  DS stage III, NST/RIC                                             88                     3.05   (2.20--4.22)     \<0.001   
  DS missing, Auto                                                  17                     1                                 
  DS missing, NST/RIC                                               10                     1.53   (0.63--3.70)     0.344     
  Relapse                                                                                                                    
  Interactional effect between main effect and Durie-Salmon Stage   DS stage I--II, Auto   40     1                          
  DS stage I--II, NST/RIC                                           54                     1.16   (0.74--1.82)     0.518     
  DS stage III, Auto                                                80                     1                                 
  DS stage III, NST/RIC                                             88                     2.70   (1.93--3.80)     \<0.001   
  DS missing, Auto                                                  17                     1                                 
  DS missing, NST/RIC                                               10                     1.51   (0.59--3.83)     0.388     
  NRM                                                                                                                        
  Main effect                                                       Auto                   137    1                          
  NST/RIC                                                           152                    7.14   (2.70--18.91)    \<0.001   

overall p-value

Auto = autotransplant

NST/RIC = non-myeloablative stem cell transplant/reduced intensity conditioning

DS = Durie-Salmon

NRM = non-relapse mortality
